Evaluation of trefoil factor 3 as a non-invasive biomarker of gastric intestinal metaplasia and gastric cancer in a high-risk population

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer in 185 countries, CA Cancer J Clin, 10.3322/caac.21660 Correa, 1975, A model for gastric cancer epidemiology, Lancet, 2, 58, 10.1016/S0140-6736(75)90498-5 Correa, 1988, A human model of gastric carcinogenesis, Cancer Res, 48, 3554 de Vries, 2008, Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands, Gastroenterology, 134, 945, 10.1053/j.gastro.2008.01.071 Pimentel-Nunes, 2019, Endoscopy, 51, 365, 10.1055/a-0859-1883 Gawron, 2020, AGA technical review on gastric intestinal metaplasia-natural history and clinical outcomes, Gastroenterology, 158, 705, 10.1053/j.gastro.2019.12.001 Rollán, 2014, Recommendations of the Chilean Association for Digestive Endoscopy for the management of gastric pre-malignant lesions, Rev Med Chile, 142, 1181, 10.4067/S0034-98872014000900013 Zullo, 2013, Intestinal metaplasia surveillance: searching for the road-map, World J Gastroenterol, 19, 1523, 10.3748/wjg.v19.i10.1523 Leung, 2008, Screening for gastric cancer in Asia: current evidence and practice, Lancet Oncol, 9, 279, 10.1016/S1470-2045(08)70072-X Plaut, 1997, Trefoil peptides in the defense of the gastrointestinal tract, N Engl J Med, 336, 506, 10.1056/NEJM199702133360712 Wong, 1999, Trefoil peptides, Gut, 44, 890, 10.1136/gut.44.6.890 Xiao, 2015, Trefoil factors: gastrointestinal-specific proteins associated with gastric cancer, Clin Chim Acta, 450, 127, 10.1016/j.cca.2015.08.004 Ge, 2015, Trefoil factor 3 (TFF3) is regulated by food intake, improves glucose tolerance and induces mucinous metaplasia, PLOS ONE, 10, e0126924, 10.1371/journal.pone.0126924 Gutierrez-Gonzalez, 2008, Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration, Dig Liver Dis, 40, 510, 10.1016/j.dld.2008.02.029 Leung, 2002, Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues, J Pathol, 197, 582, 10.1002/path.1147 Kaise, 2011, The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk, J Gastroenterol, 46, 736, 10.1007/s00535-011-0396-8 Aikou, 2011, Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening, Gastroenterology, 141, 837, 10.1053/j.gastro.2011.05.040 Huang, 2014, Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China, BMC Gastroenterol, 14, 74, 10.1186/1471-230X-14-74 Lee, 2017, Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer, Clinical Exp Med, 17, 403, 10.1007/s10238-016-0426-1 Lee, 2021, Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP), Gut, 10, 1 Ministry of Health of Chile. Mortality statistics. Information. DoHSa, editor. Available from: http://www.deis.minsal.cl/ [accessed 19.5.20]. R&D Systems, Inc., Quantikine® ELISA Human TFF3 Immunoassay, DTFF30 datasheet, 2017 [revised August 2020]. Dixon, 1996, Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994, Am J Surg Pathol, 20, 1161, 10.1097/00000478-199610000-00001 Rugge, 2000, Gastric dysplasia: the Padova international classification, Am J Surg Pathol, 24, 167, 10.1097/00000478-200002000-00001 Lauwers, 2010, 48 Dhar, 2005, Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis, Clin Cancer Res, 11, 6472, 10.1158/1078-0432.CCR-05-0671 Yamachika, 2002, Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma, Clin Cancer Res, 8, 1092 Genta, 2015, Characteristics of the gastric mucosa in patients with intestinal metaplasia, Am J Surg Pathol, 39, 700, 10.1097/PAS.0000000000000384 Kamberoglou, 2002, Prevalence and risk factors associated with specialized intestinal metaplasia at the esophagogastric junction, Hepatogastroenterology, 49, 995 Leung, 2005, Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients, Cancer Epidemiol Biomarkers Prev, 14, 2982, 10.1158/1055-9965.EPI-05-0181